Hemogenyx Pharmaceuticals PLC Presentation at the NY Oncology Investor Conf.
2019年11月6日 - 4:00PM
RNSニュース (英語)
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
06 November 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Presentation at the New York Oncology Investor Conference
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments designed to transform
bone marrow transplantation for the treatment of blood diseases,
announces that it will be presenting at the New York Oncology
Investor Conference being held on November 12 and 13 in New York,
New York.
Dr Vladislav Sandler, Chief Executive Officer, is scheduled to
present on Tuesday, November 12 at 6:10 p.m., Eastern Time with
one-on-one meetings to be held throughout the conference. The New
York Oncology Investor Conference 2019
(www.oncologyinvestorconference.com) joins the leading life science
and oncology venture capitalists, family offices, lawyers, pharma
executives, startup public and private cancer companies and cancer
foundations for a discussion on trends, opportunities and risks in
oncology investing. The conference will feature corporate
presentations by a select group of public and private oncology
companies, and updates on cutting edge science.
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
at its state-of-the-art research facility in New York City and a
wholly-owned Belgian subsidiary, Hemogenyx-Cell SPRL, located in
Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABXBDBRXGBGCU
(END) Dow Jones Newswires
November 06, 2019 02:00 ET (07:00 GMT)
Silver Falcon (LSE:SILF)
過去 株価チャート
から 5 2024 まで 6 2024
Silver Falcon (LSE:SILF)
過去 株価チャート
から 6 2023 まで 6 2024